HomeCompareGNHAY vs GIS

GNHAY vs GIS: Dividend Comparison 2026

GNHAY yields 5.29% · GIS yields 6.53%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNHAY wins by $6.17M in total portfolio value
10 years
GNHAY
GNHAY
● Live price
5.29%
Share price
$38.39
Annual div
$2.03
5Y div CAGR
62.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.25M
Annual income
$4,849,407.89
Full GNHAY calculator →
GIS
GIS
● Live price
6.53%
Share price
$37.22
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.8K
Annual income
$16,211.26
Full GIS calculator →

Portfolio growth — GNHAY vs GIS

📍 GNHAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNHAYGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNHAY + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNHAY pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNHAY
Annual income on $10K today (after 15% tax)
$449.27/yr
After 10yr DRIP, annual income (after tax)
$4,121,996.71/yr
GIS
Annual income on $10K today (after 15% tax)
$554.94/yr
After 10yr DRIP, annual income (after tax)
$13,779.57/yr
At 15% tax rate, GNHAY beats the other by $4,108,217.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNHAY + GIS for your $10,000?

GNHAY: 50%GIS: 50%
100% GIS50/50100% GNHAY
Portfolio after 10yr
$3.16M
Annual income
$2,432,809.58/yr
Blended yield
76.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GIS right now

GNHAY
No analyst data
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.4% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNHAY buys
0
GIS buys
0
No recent congressional trades found for GNHAY or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNHAYGIS
Forward yield5.29%6.53%
Annual dividend / share$2.03$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR62.6%22.8%
Portfolio after 10y$6.25M$78.8K
Annual income after 10y$4,849,407.89$16,211.26
Total dividends collected$6.10M$50.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: GNHAY vs GIS ($10,000, DRIP)

YearGNHAY PortfolioGNHAY Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$11,559$859.42$11,502$801.73+$57.00GNHAY
2$13,878$1,509.66$13,365$1,058.29+$513.00GNHAY
3$17,604$2,754.33$15,712$1,411.34+$1.9KGNHAY
4$24,146$5,309.21$18,716$1,904.17+$5.4KGNHAY
5$36,902$11,066.02$22,629$2,603.16+$14.3KGNHAY
6$65,185$25,700.29$27,826$3,612.21+$37.4KGNHAY
7$138,737$68,988.48$34,871$5,097.54+$103.9KGNHAY
8$371,577$223,128.79$44,643$7,331.52+$326.9KGNHAY
9$1,305,722$908,134.35$58,541$10,772.15+$1.25MGNHAY
10$6,246,530$4,849,407.89$78,850$16,211.26+$6.17MGNHAY

GNHAY vs GIS: Complete Analysis 2026

GNHAYStock

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of March 22, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.

Full GNHAY Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this GNHAY vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNHAY vs SCHDGNHAY vs JEPIGNHAY vs OGNHAY vs KOGNHAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.